Intercept of minute ventilation vs. carbon dioxide output relationship in chronic obstructive pulmonary disease: utility as an index of ventilatory inefficiency

CURRENT STATUS: UNDER REVIEW

BMC Pulmonary Medicine  BMC Series

Haoyan Wang
Capital Medical University Affiliated Beijing Friendship Hospital

haoyanw@126.com Corresponding Author
ORCID: https://orcid.org/0000-0003-3267-8396

Fang Lin
Capital Medical University Affiliated Beijing Friendship Hospital

Shan Nie
Capital Medical University Affiliated Beijing Friendship Hospital

Ranran Zhao
Capital Medical University Affiliated Beijing Friendship Hospital

Min Cao
Capital Medical University Affiliated Chest Hospital

Wei Yuan
Capital Medical University Affiliated Beijing Friendship Hospital

Yunxiao Li
Capital Medical University Affiliated Beijing Friendship Hospital

Chunting Tan
Capital Medical University Affiliated Beijing Friendship Hospital

Bo Xu
Capital Medical University Affiliated Beijing Friendship Hospital

DOI:
10.21203/rs.3.rs-19544/v1

SUBJECT AREAS
Pulmonology
KEYWORDS
chronic obstructive pulmonary disease, ventilatory inefficiency, exercise, lung hyperinflation, airflow limitation
Abstract

**Background:** Ventilatory inefficiency is known to be a contributor to exercise intolerance in chronic obstructive pulmonary disease (COPD). The intercept of the minute ventilation ($V_E$) vs. carbon dioxide output ($VCO_2$) plot is a key ventilator inefficiency parameter. However, its relationships with lung hyperinflation (LH) and airflow limitation are not known. This study aimed to evaluate the correlations between the $V_E/VCO_2$ intercept and LH in COPD to determine its utility as an index of functional impairment.

**Methods:** We conducted a retrospective analysis of data from 53 COPD patients and 14 healthy controls performed incremental cardiopulmonary exercise tests and resting pulmonary function. Ventilatory inefficiency was represented by parameters reflecting the $V_E/VCO_2$ nadir and slope (linear region), and intercept of the $V_E/VCO_2$ plot. Their correlations with measures of LH and airflow limitation were evaluated.

**Results:** Compared to the control, the slope (30.58±3.62) and intercept (4.85±1.11) higher in COPD _stages 1-2_, leading to a higher nadir (31.47±4.47) ($p<0.05$). Despite an even higher intercept in COPD _stages 3-4_ (7.16±1.41), the slope diminished with disease progression (from 30.58±3.62 in COPD _stages 1-2_ to 28.36±4.58 in COPD _stages 3-4_). Compared to the $V_E/VCO_2$ nadir and $V_E/VCO_2$ slope, the intercept was better correlated with peak $V_E$/maximal voluntary ventilation (MVV) ($r=0.489$, $p<0.001$) and peak VO$_2$/watt ($r=0.354$, $p=0.003$). The intercept was also significantly correlated with RV/TLC ($r=0.588$, $p<0.001$), IC/TLC ($r=-0.574$, $p<0.001$), peak $V_T$/TLC ($r=-0.585$, $p<0.001$); and airflow limitation forced expiratory volume in 1s (FEV$_1$) % predicted ($r=-0.606$, $p<0.001$) and FEV$_1$/forced vital capacity (FVC) ($r=-0.629$, $p<0.001$).

**Conclusion:** $V_E/VCO_2$ intercept was consistently better correlated with worsening static and dynamic lung hyperinflation and airflow limitation in COPD. $V_E/VCO_2$ intercept emerged as a useful index of ventilatory inefficiency across the severity spectrum of COPD patients.

**Background**

Activity-related dyspnea is the defining complaint in patients with chronic obstructive pulmonary
disease (COPD) [1]. The limitations in activity and dyspnea are multifactorial. The development of lung hyperinflation (LH) plays an important role in the pathophysiology of dyspnea and exercise intolerance [2]. Static hyperinflation which is caused by destructions of pulmonary parenchyma and loss of lung elastic recoil is characterized by increased functional residual capacity (FRC) and reduced inspiratory capacity (IC) [3]. Dynamic hyperinflation which occurs when the expiratory time becomes insufficient to allow the lung to achieve full exhalation yields an increased end-expiratory lung volume (EELV) during exercise [4]. LH increases ventilatory workload and decreases inspiratory muscle pressure generating capacity, despite some compensatory mechanisms [3]. The diminished ventilatory capacity coupled with the increased ventilatory demand during exercise yields exercise intolerance.

The minute ventilation ($V_E$) vs. carbon dioxide production ($V_{CO_2}$) relationship is a measure of the ventilatory efficiency at removing $CO_2$ produced by the body. Early in exercise, $V_E/V_{CO_2}$ decreases with a decrease in dead space ventilation ($V_D$)/tidal volume ($V_T$) ratio. The $V_E/V_{CO_2}$ nadir is typically reached just before ventilation starts to increase to compensate for lactic acidosis at the respiratory compensation point [5]. The $V_E/V_{CO_2}$ nadir was found to be highly reproducible in healthy subjects [6] and COPD patients [7]. However, the $V_E/V_{CO_2}$ nadir might underestimate ventilatory efficiency if the descending curve is prematurely interrupted by lactic acidosis or an excessively short test duration [8]. On the other hand, $V_E/V_{CO_2}$ ratio might higher than the nadir as the hyperventilation response to late-exercise acidosis in patients who are able to can exercise beyond the respiratory compensation point [9].

The $V_E/V_{CO_2}$ slope has been used to assess disease progression and to identify the presence of comorbidities [10-15]. However, in many patients with moderate-to-severe COPD, concomitant increases in the partial pressure of carbon dioxide (PaCO$_2$) and mechanical constraints will predictably flatten the $V_E/V_{CO_2}$ curve. In these patients, the $V_E/V_{CO_2}$ slope might, paradoxically, decrease as the disease evolves if $CO_2$ retention during exercise worsens. It is plausible that the
\( \dot{V}_E/\dot{V}CO_2 \) nadir might be stable while the slope and intercept change in opposite directions despite COPD progression [9].

Theoretically, the y-intercept of the \( \dot{V}_E/\dot{V}CO_2 \) plot (intercept = \( \dot{V}_E \) when \( \dot{V}CO_2 = 0 \), that is, in the absence of pulmonary gas exchange) corresponds to the basal \( \dot{V}_E \) that contributes to the wasted \( V_D \) [16]. By definition, the intercept cannot be constrained by dynamic mechanics (unlike the slope) or the test duration (unlike the nadir). The increased intercept in COPD patients theoretically results from dead space (when metabolic demand is null) and might result from an altered breathing strategy (increased breathing frequency to compensate for reduced \( V_T \) secondary to greater mechanical constraints) and/or a progressive ventilation-perfusion mismatch in COPD patients [1]. Thus, the \( \dot{V}_E/\dot{V}CO_2 \) intercept increases with greater disease severity in COPD patients, and it seems to be a particularly useful index for ventilatory inefficiency across the continuum of COPD severity [9]. However, the clinical implications of the \( \dot{V}_E/\dot{V}CO_2 \) intercept and its association with LH in COPD have not been formally examined.

This study aimed to evaluate the relationship between the \( \dot{V}_E/\dot{V}CO_2 \) intercept and LH and airflow limitation in patients with COPD. We hypothesized that the \( \dot{V}_E/\dot{V}CO_2 \) intercept correlated well with measures of both LH and airflow limitation and could be used as a particularly useful index for ventilatory inefficiency in COPD.

**Methods:**

**Study participants**

This study was a retrospective analysis of data collected during incremental cardiopulmonary exercises from ethically-approved research studies on COPD at the Respiratory Investigation Unit, Beijing Friendship Hospital, Capital Medical University (Beijing, China). Participants were males and females aged ≥ 40 years with body mass index (BMI) of 18–35 kg/m\(^2\). The patients were current or ex-smokers (smoking history ≥ 10 pack-years) and had a well-established diagnosis of COPD [17] without asthma or other pulmonary diseases. Patients were required to have had no exacerbation in the preceding 6 weeks. Control subjects with no smoking history were in the same age range and they
had no major orthopedic, neuromuscular, cardiac or metabolic diseases, to allow them to safely undertake the incremental exercise tests.

**Pulmonary Function Tests**
Each subject underwent resting spirometry (MasterScreen Body, CareFusion, Hoechberg, Germany), including inspiratory capacity (IC) assessment. Body plethysmography was performed to measure residual volume (RV), total lung capacity (TLC) and diffusing capacity of the lungs for carbon monoxide (DLCO). Patients took 400 µg albuterol by inhalation 20 min before testing. All pulmonary function tests fulfilled the American Thoracic Society/European Respiratory Society guidelines [18].

**Cardiopulmonary Exercise Test (CPET)**
Symptom-limited incremental exercise testing was performed on an electronically braked cycle ergometer (ViaSprint, CareFusion, Hoechberg, Germany) with a pedaling rate of 60/min. After 3 min of rest and 3 min of unloaded pedaling, the work rate (WR) was increased by 5–15 W/min in a ramp fashion (5 W/min if FEV1 < 1.0 L and 10 W/min if FEV1 ≥ 1.0 L for the COPD patients; 15 W/min for the controls, with repetition at 20 W/min if the peak WR was ≥ 200 W). Participants were asked to continue to exercise to the limit of tolerance, marked by the inability (despite encouragement) to maintain pedaling frequency or intolerable shortness of breath. Any participant with chest pain suggestive of ischemia, ventricular tachycardia and blood pressure (BP) ≥ 240/130 mmHg was prevented further exercise. Patients were continuously monitored with a 12-lead electrocardiogram and blood pressure by sphygmomanometer every 2 min.

**Data Collection**
Respiratory gas exchange (VE, VO2, and VCO2) and VT were measured breath-by-breath throughout the exercise testing. Serial measurements of these parameters were averaged at 30-s intervals. Arterial oxygen saturation was measured noninvasively by pulse oximetry (SpO2; %). The VE/VCO2 nadir and peak were the lowest and the mean of the last 30-s of data, respectively [19]. The slope of the VE/VCO2 relationship was determined based on the VE vs.VCO2 plot (VE on the y-axis and VCO2 on the x-axis). A linear regression line was determined based on these data points [19, 20] from the start of loading exercise to the nadir. The VE/VCO2 intercept was calculated by extrapolating the regression
line to VCO₂ = 0. Maximal voluntary ventilation (MVV) was calculated as FEV₁ × 4.0. Peak VT/TLC, was used as measures dynamic LH during exercise while IC/TLC and RV/TLC were used as static LH [21].

Statistical analysis
Values are reported as mean ± SD unless otherwise stated. P-value < 0.05 was considered significant in all analyses. Intraclass correlation coefficients were used to determine the level of between-investigator agreement in the calculation of the slope and intercept. Between-group comparisons were performed using one-way analysis of variance (ANOVA) with LSD post-hoc testing of significant variables. Pearson’s correlation coefficient (r) was used to assess the correlations between the ventilatory inefficiency parameters (VE/VCO₂ intercept, slope and nadir) and ventilatory capacity (peak VE/MVV, peak VO₂/watt), static or dynamic hyperinflation measures (RV/TLC, IC/TLC and peak VT/TLC), and airflow limitation (FEV₁% predicted and FEV₁/FVC). All analyses were performed with IBM SPSS Statistics 20.0 (Chicago, USA).

Results
Participant characteristics and resting spirometric measurements
As shown in Table 1, the COPD stages1−2 (n = 35), COPD stages3−4 (n = 18) and control (n = 14) were well matched in terms of age, weight, and BMI. The resting spirometric measures of the participants presented in Table 1. There are the expected decreases in FEV₁ % predicted, FEV₁/FVC, IC % predicted, IC/TLC, DL_CO % predicted and the expected increases in RV%, RV/TLC, FRC/TLC from COPD stages1−2 to COPD stages3−4 (p < 0.01). Table 1 shows demographics and selected resting pulmonary function variables in control and COPD patients.
Exercise Characteristics

All subjects completed the exercise testing without complications. Peak exercise capacity was progressively reduced from the control to COPD_{stages1−2} and COPD_{stages3−4} patients. Measures at peak exercise showed that the COPD_{stages3−4} patients had significantly reduced \( V_{E} \), \( V_{O_2} \), \( VO_{2\%} \), \( VO_{2/HR} \), \( VCO_2 \) and \( WR \) in comparison to the control \((p < 0.001)\) (Table 2). During exercise, the peak \( V_T \) in COPD_{stages3−4} \((1.3 \pm 0.2)\) was lower than in COPD_{stages1−2} \((1.64 \pm 0.35)\).

COPD groups were significantly lower than the control \((1.79 \pm 0.22)\), \((p < 0.05)\). Regarding the measures of DH \((peak V_T/TLC)\), COPD_{stages1−2} \((27.45 \pm 5.02)\) and COPD_{stages3−4} \((19.88 \pm 4.78)\) patients all exhibited significant difference compared to the control \((33.15 \pm 5.5)\) \((p < 0.01)\; Table 2 shows the exercise variables at peak exercise in the control and COPD patients categorized by GOLD.
Table 2
Selected variables at peak exercise in control and COPD patients.

| Variable                  | Control (n = 14) | COPD stages1−2 (n = 35) | COPD stages3−4 (n = 18) | ANOVA P-value |
|---------------------------|------------------|--------------------------|--------------------------|---------------|
| VO₂ (L/min)               | 1.77 ± 0.34      | 1.37 ± 0.27***           | 1.14 ± 0.26***##         | 0.000         |
| VO₂% predicted (%)        | 99 ± 17.2        | 77.29 ± 12.47***         | 50.94 ± 12.25****       | 0.000         |
| VO₂/HR (ml)               | 11.92 ± 2.03     | 10.37 ± 1.77**           | 9.39 ± 1.49***          | 0.001         |
| VE/L/min                  | 59.21 ± 13.93    | 53.71 ± 11.02            | 40.94 ± 8.61***##       | 0.000         |
| VC O₂ (L/min)             | 2.1 ± 0.44       | 1.63 ± 0.34***           | 1.25 ± 0.31***##        | 0.000         |
| VE/VO₂                    | 33.37 ± 4.43     | 39.49 ± 6.17*            | 36.84 ± 7.32            | 0.009         |
| VE/VCO₂                   | 27.65 ± 3.12     | 32.51 ± 4.78**           | 32.48 ± 6.08**          | 0.007         |
| VE/MVV (%)                | 53.29 ± 12.04    | 69.17 ± 12.67**          | 89.52 ± 17.7***##       | 0.000         |
| WR (watt)                 | 140.79 ± 25.16   | 107.26 ± 24.92***        | 80.44 ± 16.86****       | 0.000         |
| VO₂/watt (ml/min/watt)    | 12.65 ± 1.6      | 12.97 ± 1.33             | 14.14 ± 1.51**          | 0.007         |
| VT (L)                    | 33.15 ± 5.5      | 27.45 ± 5.02**           | 19.88 ± 4.78**          | 0.000         |

Data are presented as mean ± standard deviation. VO₂: oxygen uptake; VE: minute ventilation; VCO₂: carbon dioxide output; HR: heart rate; MVV: maximal voluntary ventilation; WR: work rate; VT: tidal volume; TLC: total lung capacity. The * and # labeled for results of the post-hoc test. *p < 0.05 vs. control; **p < 0.01 vs. control; ***p < 0.001 vs. control; #p < 0.05 COPD stages3−4 vs. COPD stages1−2; ## p < 0.01 COPD stages3−4 vs. COPD stages1−2; ### p < 0.001 COPD stages3−4 vs. COPD stages1−2

Ventilatory Inefficiency in COPD Patients

The VE/VCO₂ relationships were expressed in terms of the slope, nadir, and intercept. Compared to control (24.75 ± 3.07), the slope was increased in COPD stages1−2 (30.58 ± 3.62) and decreased in COPD stages3−4 (26.84 ± 4.96). As for the intercept, the COPD stages1−2 and COPD stages3−4 had higher intercepts (4.85 ± 1.11 and 7.16 ± 1.41, respectively) in comparison to control (3.91 ± 1.03). There were significant differences between COPD patients and control (p < 0.05). Furthermore, VE/VCO₂ intercept increased across the severity spectrum of COPD (p < 0.001). The nadir was increased in COPD stages1−2 (31.47 ± 4.47) and almost stable in COPD stages3−4 (32.82 ± 5.29) in comparison to control (26.9 ± 2.92). Among ventilatory inefficiency parameters (slope, nadir and intercept), only VE/VCO₂ intercept exhibited a better correlation with peak VO₂/watt (r = 0.354, p = 0.003) and peak VE/MVV (r = 0.489, p < 0.001). Figure 1 shows measures of ventilatory inefficiency in control and COPD patients. Figure 2 shows VE/VCO₂ intercept in correlation with peak VE/MVV and peak VO₂/watt in the entire study group.

Correlation of ventilatory inefficiency with lung hyperinflation and airflow limitation
The relationships between the measures of ventilatory inefficiency and lung hyperinflation and airflow limitation were assessed in COPD patients. The $V_\text{E}/V\text{CO}_2$ intercept was better correlated with rest IC/TLC ($r=-0.574, p < 0.001$), RV/TLC ($r = 0.588, p < 0.001$) compared to the $V_\text{E}/V\text{CO}_2$ slope with rest IC/TLC ($r=-0.006, p = 0.962$), RV/TLC ($r = 0.191, p = 0.121$) and the $V_\text{E}/V\text{CO}_2$ nadir with rest IC/TLC ($r=-0.35, p = 0.004$), RV/TLC ($r = 0.431, p < 0.001$). The intercept also exhibited better correlation with peak $V_T$/TLC ($r=-0.585, p < 0.001$) than the nadir with peak $V_T$/TLC ($r=-0.503, p < 0.001$) and the slope with peak $V_T$/TLC ($r=-0.148, p = 0.232$)

A similar pattern of results was found in relation to airflow limitation. $V_\text{E}/V\text{CO}_2$ slope was not correlated with FEV$_1$% predicted ($r=-0.064, p = 0.609$) or FEV$_1$/FVC ($r=-0.167, p = 0.178$). The intercept showed significantly correlation with FEV$_1$% predicted ($r=-0.606, p < 0.001$) and FEV$_1$/FVC ($r=-0.629, p < 0.001$) compared to the $V_\text{E}/V\text{CO}_2$ nadir with FEV$_1$% predicted ($r=-0.368, p = 0.002$) and FEV$_1$/FVC ($r = 0.434, p < 0.001$). Table 3 shows the correlations between the ventilatory inefficiency parameters and measures of lung hyperinflation and airflow limitation. Figure 3 shows $V_\text{E}/V\text{CO}_2$ intercept significant correlations with peak $V_T$/TLC, IC/TLC, RV/TLC, and FEV$_1$% predicted in the entire study group.

**Table 3**

|                     | $V_\text{E}/V\text{CO}_2$ slope | $V_\text{E}/V\text{CO}_2$ nadir | $V_\text{E}/V\text{CO}_2$ intercept |
|---------------------|---------------------------------|---------------------------------|-------------------------------------|
| peak $V_T$/TLC      | -0.148                          | -0.503                          | -0.585                              |
| IC/TLC, %           | -0.006                          | -0.35                           | -0.574                              |
| RV/TLC, %           | 0.191                           | 0.431                           | 0.588                               |
| FEV$_1$/FVC, %      | -0.167                          | -0.434                          | -0.629                              |
| FEV$_1$ % predicted, % | -0.064                          | -0.368                          | -0.606                              |

V$_T$: tidal volume; IC: inspiratory capacity; TLC: total lung capacity; FEV$_1$: forced expiratory volume in 1 s; FVC: forced vital capacity.

**Discussion**

The main finding of this study was that $V_\text{E}/V\text{CO}_2$ intercept was consistently correlated with worsening LH and increasing airflow limitation in COPD. $V_\text{E}/V\text{CO}_2$ intercept could be a useful index for ventilatory inefficiency during incremental exercise in COPD.
$V_E/VCO_2$ relationship was analyzed according to the $V_E/VCO_2$ ratio vs. time plot [22]. For healthy subjects who can tolerate high levels of exercise, the $V_E/VCO_2$ nadir and $V_E/VCO_2$ ratio at the anaerobic threshold were usually very similar [6]. Abnormalities in the $V_E/VCO_2$ relationship were present across the spectrum of COPD severity. The $V_E/VCO_2$ nadir showed superior test-retest reliability compared to the $V_E/VCO_2$ slope in COPD patients [23]. Increases both in $V_E/VCO_2$ nadir and slope were associated with lower maximal exercise capacity in COPD patients [24, 25]. A retrospective study with a large range of resting pulmonary function (FEV$_1$ = 12–148% predicted) showed an increased $V_E/VCO_2$ slope in mild-moderate COPD but a decreased slope in advanced stage in comparison to control. As for $V_E/VCO_2$ nadir, there was no significant difference in different stages. However, the $V_E/VCO_2$ intercept was higher across all stages of COPD [9]. In our study, compared to control, COPD$_{stages1−2}$ had a higher slope and nadir, while patients with more advanced stages (COPD$_{stages3−4}$) had a lower slope and a stable nadir (i.e., with no significant change compared to COPD$_{stages1−2}$). The $V_E/VCO_2$ intercept increased from COPD$_{stages1−2}$ to COPD$_{stages3−4}$. In advanced-stage COPD, the stable $V_E/VCO_2$ nadir likely reflected the opposite changes in the $V_E/VCO_2$ slope and intercept. There was mounting evidence that ventilatory inefficiency parameters were powerful prognostic predictors in COPD patients with comorbidity. A retrospective study in 145 COPD patients undergoing surgery for non-small cell cancer showed that $VE/VCO2$ slope > 34 predicted mortality after lung resection surgery [26]. As for the $VE/VCO2$ nadir, Neder et al. reported that the nadir > 34 in combination with resting hyperinflation predicted mortality in COPD [27]. Importantly, a series of studies demonstrated that the $VE/VCO2$ intercept (cutoff values ranging from 2.64–4.07 L/min) might discriminate COPD from heart failure [28, 29]. Ventilatory inefficiency increases ventilatory demand and exercise capacity limitation due to expiratory flow limitation that enhances dynamic hyperinflation. Two other independent studies showed correlations between the $V_E/VCO_2$ nadir and emphysema severity on high-resolution
computed tomography scans in COPD patients with largely preserved FEV$_1$ [30, 31]. Static LH caused by reduction of elastic recoil due to emphysema in COPD and development of expiratory flow limitation promoted progressive air trapping with an increase in the EELV and a decrease in IC. RV was also increased in emphysema/COPD because of both loss of elastic recoil and premature closure of the small airways [32–34]. In expiratory flow-limited patients, EELV was a continuous dynamic variable, which depended on expiratory duration and breathing pattern. DH referred to this temporary and variable increase in EELV. DH was a consequence as ventilation increases and expiratory duration decreases, there was not enough time to allow EELV to decline to its baseline resting value during exercise [35].

Studies reported both static hyperinflation and the degree of dynamic lung hyperinflation were associated with the development of dyspnea and exercise intolerance in COPD patients [36, 37]. Assuming stability of TLC, the resting IC and inspiratory reserve (IRV) showed the operating position of V$_T$ relative to TLC. The smaller the resting IC, the shorter the exercise time before V$_T$ reached plateau and dyspnea abruptly escalates [38]. A four-year longitudinal study reported that significant reductions in peak VO$_2$ and V$_E$ were related to a decrease in resting IC [39]. Both IC/TLC and RV/TLC in patients with COPD reflected not only the degree of lung static hyperinflation but also the functional reserve. IC/TLC was also found to be a valuable and independent predictor of all-cause and respiratory mortality in COPD compared with that of the BODE (body mass index, airflow obstruction, dyspnea, exercise performance) index [40]. The present study showed V$_E$/VCO$_2$ intercept exhibited better correlated with rest IC/TLC (r=-0.574, p < 0.001) and RV/TLC (r = 0.588, p < 0.001) than V$_E$/VCO$_2$ nadir with peak IC/TLC (r=-0.350, p = 0.004) and RV/TLC (r = 0.431, p < 0.001) while V$_E$/VCO$_2$ slope had no correlation with static LH parameters.

The EELV progressively increases while IC decreases were associated with dyspnea and exercise intolerance in COPD during exercise [41]. Serial measurements of IC to detect its changes had been reported to be a classic way to identify dynamic hyperinflation [36, 37, 42]. However, the study participates had to be familiar with the maneuvers, and IC measurements also had to be standardized.
by researchers [43]. Nevertheless, dynamic IC measurement was not recommended for ramp-pattern protocols where VT cannot steadily proceed to perform IC maneuver. However, the ramp-pattern protocol was a widely used for incremental test [43]. Elevated EELV can substantially constrain the expansion of VT at higher exercise intensities. It followed that COPD patients reached a VT plateau and a similar minimal inspiratory reserve volume. Chuang et al. investigated peak VT/TLC as a convenient new marker of DH and the cutoff value was 0.27 [44]. The present results showed among ventilatory inefficiency parameters (slope, nadir and intercept), only VE/VCO₂ intercept exhibited better correlated with peak VT/TLC (r=-0.585, p < 0.001) than VE/VCO₂ nadir with peak VT/TLC (r=-0.503, p < 0.001) and VE/VCO₂ slope with peak VT/TLC (r=-0.148, p = 0.232). To our knowledge, this is the first study to describe the relationship between ventilatory inefficiency and DH. Interestingly, the VE/VCO₂ intercept was better correlated with worsening pulmonary airflow limitation, FEV₁/FVC (r=-0.629, p < 0.001) and FEV₁% predicted (r=-0.606, p < 0.001), than with the other ventilator inefficiency parameters.

A limitation of our study is the modest number of subjects. We believe that the increased ventilatory inefficiency associated with LH might be more pronounced in patients with more advanced COPD. However, in the absence of a true criterion test for ventilatory inefficiency during exercise, we relied on a cluster of variables that were indirect markers of pulmonary gas-exchange disturbances. We also recognize that variables related to disease phenotypes and test factors (e.g., duration) affect the different strategies to reflect ventilatory inefficiency.

**Conclusion**

VE/VCO₂ intercept, by definition, equals basal VE when VCO₂ equals zero, that is, in the absence of pulmonary gas exchange. VE/VCO₂ intercept cannot be constrained by dynamic mechanics (unlike the slope) or the test duration (unlike the nadir). Increases in VE/VCO₂ intercept correlated well with worsening static and dynamic lung hyperinflation and resting airflow limitation. VE/VCO₂ intercept increased across the severity spectrum of COPD. A hitherto underappreciated variable, the VE/VCO₂ intercept, was found to be a particularly useful index for ventilatory inefficiency during incremental
exercise in COPD patients.

Abbreviations

BMI
body mass index;

COPD
chronic obstructive pulmonary disease;

CPET
cardiopulmonary exercise test;

LH
lung hyperinflation;

DL\textsubscript{CO}
diffusing capacity of the lungs for carbon monoxide;

EELV
end-expiratory lung volume;

FEV\textsubscript{1}
forced expiratory volume in 1 s;

FRC
functional residual capacity;

FVC
forced vital capacity;

GOLD
Global Initiative for Chronic Obstructive Lung Disease;

IC
inspiratory capacity;

MVV
maximal voluntary ventilation;

RV
residual volume;

SpO\textsubscript{2}
oxygen saturation via pulse oximetry;

TLC
total lung capacity;

VCO\textsubscript{2}
carbon dioxide output;
$V_E$
minute ventilation;
$V_O2$
oxygen uptake;
$V_D$
dead space ventilation;
$V_T$
tidal volume
$WR$
work rate;

Declarations

Acknowledgements

The authors would like to thank Nan Jia, Xujuan Zhao, and Bin Li from the pulmonary function investigation unit of the Department of Respiratory Beijing Friendship Hospital, Capital Medical University for performing the lung function test and the medical support during the execution of the CPET.

Funding

This study was supported by the Capital’s Funds for Health Improvement and Research (No. 2018-2-2-24, Beijing, China).

Availability of data and materials

The datasets used and analyzed in the present study will be available from the corresponding author on reasonable request.

Authors’ contributions

Haoyan Wang and Bo Xu participated in the conception, the design and coordination of the study.
Fang Lin collected data, interpreted the patient data and drafted the manuscript. Min Cao participated in its coordination and helped to draft the manuscript. Shan Nie, Ranran Zhao, Wei Yuan Yunxiao Li, Chunting Tan participated in collecting data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the ethics committee of the Beijing Friendship Hospital and the written
informed consent was obtained from every participant.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. O'Donnell DE, Laveneziana P, Webb K, Neder JA. *Chronic obstructive pulmonary disease: clinical integrative physiology*. *Clin Chest Med* 2014, **35**(1):51-69.

2. Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D. *Pathogenesis of hyperinflation in chronic obstructive pulmonary disease*. *Int J Chron Obstruct Pulmon Dis* 2014, **9**:187-201.

3. Cooper CB. *The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function*. *Am J Med* 2006, **119**(10 Suppl 1):21-31.

4. Varga J. *Mechanisms to dyspnoea and dynamic hyperinflation related exercise intolerance in COPD*. *Acta Physiol Hung* 2015, **102**(2):163-175.

5. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, et al. *Recommendations on the use of exercise testing in clinical practice*. *Eur Respir J* 2007, **29**(1):185-209.

6. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. *Ventilatory efficiency during exercise in healthy subjects*. *Am J Respir Crit Care Med* 2002, **166**(11):1443-1448.

7. Barron A, Dhutia N, Mayet J, Hughes AD, Francis DP, Wensel R. *Test-retest repeatability of cardiopulmonary exercise test variables in patients with cardiac or respiratory disease*. *Eur J Prev Cardiol* 2014, **21**(4):445-453.

8. Neder JA, Nery LE, Peres C, Whipp BJ. *Reference values for dynamic responses to*
incremental cycle ergometry in males and females aged 20 to 80. *Am J Respir Crit Care Med* 2001, **164**(8 Pt 1):1481-1486.

9. Neder JA, Arbex FF, Alencar MC, O'Donnell CD, Cory J, Webb KA, O'Donnell DE. **Exercise ventilatory inefficiency in mild to end-stage COPD.** *Eur Respir J* 2015, **45**(2):377-387.

10. Paoletti P, De Filippis F, Fraioli F, Cinquanta A, Valli G, Laveneziana P, Vaccaro F, Martolini D, Palange P. **Cardiopulmonary exercise testing (CPET) in pulmonary emphysema.** *Respir Physiol Neurobiol* 2011, **179**(2-3):167-173.

11. Chin RC, Guenette JA, Cheng S, Raghavan N, Amornputtsathaporn N, Cortes-Telles A, Webb KA, O'Donnell DE. **Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease?** *Am J Respir Crit Care Med* 2013, **187**(12):1315-1323.

12. Thirapatarapong W, Armstrong HF, Bartels MN. **Comparison of cardiopulmonary exercise testing variables in COPD patients with and without coronary artery disease.** *Heart Lung* 2014, **43**(2):146-151.

13. Guazzi M, Myers J, Vicenzi M, Bensimhon D, Chase P, Pinkstaff S, Arena R. **Cardiopulmonary exercise testing characteristics in heart failure patients with and without concomitant chronic obstructive pulmonary disease.** *Am Heart J* 2010, **160**(5):900-905.

14. Holverda S, Bogaard HJ, Groepenhoff H, Postmus PE, Boonstra A, Vonk-Noordegraaf A. **Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension.** *Respiration* 2008, **76**(2):160-167.

15. Vonbank K, Funk GC, Marzluf B, Burian B, Ziesche R, Stiebellehner L, Petkov V, Haber P. **Abnormal pulmonary arterial pressure limits exercise capacity in patients**
with COPD. Wien Klin Wochenschr 2008, 120(23-24):749-755.

16. Ward SA, Whipp BJ. Ventilatory control during exercise with increased external dead space. J Appl Physiol Respir Environ Exerc Physiol 1980, 48(2):225-231.

17. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017, 195(5):557-582.

18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338.

19. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med 2002, 166(11):1443-1448.

20. Neder JA, Nery LE, Peres C, Whipp BJ. Reference values for dynamic responses to incremental cycle ergometry in males and females aged 20 to 80. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1481-1486.

21. van Geffen WH, Kerstjens HA. Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2018, 13:1269-1277.

22. Cotes JE, Reed JW. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007, 29(5):1064-1066; author reply 1066-1067.

23. Barron A, Dhutia N, Mayet J, Hughes AD, Francis DP, Wensel R. Test-retest repeatability of cardiopulmonary exercise test variables in patients with cardiac or respiratory disease. European Journal of Preventive Cardiology 2014,
24. Caviedes IR, Delgado I, Soto R. **Ventilatory Inefficiency as a Limiting Factor for Exercise in Patients With COPD.** *Respiratory Care* 2012, **57**(4):583-589.

25. Teopompi E, Tzani P, Aiello M, Gioia MR, Marangio E, Chetta A. **Excess ventilation and ventilatory constraints during exercise in patients with chronic obstructive pulmonary disease.** (1878-1519 (Electronic)).

26. Torchio R, Guglielmo M, Giardino R, Ardissone F, Ciacco C, Gulotta C, Veljkovic A, Bugiani M. **Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer.** *Eur J Cardiothorac Surg* 2010, **38**(1):14-19.

27. Neder JA, Alharbi A, Berton DC, Alencar MC, Arbex FF, Hirai DM, Webb KA, O'Donnell DE. **Exercise Ventilatory Inefficiency Adds to Lung Function in Predicting Mortality in COPD.** *COPD* 2016, **13**(4):416-424.

28. Smith JR, Van Iterson EH, Johnson BD, Borlaug BA, Olson TP. **Exercise ventilatory inefficiency in heart failure and chronic obstructive pulmonary disease.** *Int J Cardiol* 2019, **274**:232-236.

29. Apostolo A, Laveneziana P, Palange P, Agalbato C, Molle R, Popovic D, Bussotti M, Internullo M, Sciomer S, Bonini M, et al. **Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure.** *Int J Cardiol* 2015, **189**:134-140.

30. Jones JH, Zelt JT, Hirai DM, Diniz CV, Zaza A, O'Donnell DE, Neder JA. **Emphysema on Thoracic CT and Exercise Ventilatory Inefficiency in Mild-to-Moderate COPD.** *COPD* 2017, **14**(2):210-218.

31. Crisafulli E, Alfieri V, Silva M, Aiello M, Tzani P, Milanese G, Bertorelli G, Sverzellati N, Chetta A. **Relationships between emphysema and airways metrics at High-
Resolution Computed Tomography (HRCT) and ventilatory response to exercise in mild to moderate COPD patients. (1532-3064 (Electronic)).

32. Gibson GJ. Pulmonary hyperinflation a clinical overview. Eur Respir J 1996, 9(12):2640-2649.

33. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, Roche N, Similowski T, Watz H, Worth H, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med 2015, 109(7):785-802.

34. Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir J 2010, 35(3):676-680.

35. Laveneziana P, Guenet JE, Webb KA, O'Donnell DE. New physiological insights into dyspnea and exercise intolerance in chronic obstructive pulmonary disease patients. Expert Rev Respir Med 2012, 6(6):651-662.

36. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(5):770-777.

37. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993, 148(5):1351-1357.

38. O'Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: New Mechanistic Insights and Management Implications. Adv Ther 2020, 37(1):41-60.

39. Frisk B, Hardie JA, Espehaug B, Strand LI, Moe-Nilssen R, Eagan TM, Bakke PS, Thorsen E. Peak oxygen uptake and breathing pattern in COPD patients--a four-year longitudinal study. BMC Pulm Med 2015, 15:93.

40. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR.
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005, 171(6):591-597.

41. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. *Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD*. *Eur Respir J* 2004, 23(6):832-840.

42. Casaburi R, Rennard SI. *Exercise limitation in chronic obstructive pulmonary disease. The O'Donnell threshold*. *Am J Respir Crit Care Med* 2015, 191(8):873-875.

43. Guenette JA, Chin RC, Cory JM, Webb KA, O'Donnell DE. *Inspiratory Capacity during Exercise: Measurement, Analysis, and Interpretation*. *Pulm Med* 2013, 2013:956081.

44. Chuang ML, Hsieh MJA-Ohoo, Wu TC, Lin IF. *Developing a New Marker of Dynamic Hyperinflation in Patients with Obstructive Airway Disease - an observational study*. (2045-2322 (Electronic)).

Figures
 Measures of ventilatory inefficiency in control and COPD patients. (A) VE/VCO2 intercept, (B) VE/VCO2 nadir, and (C) VE/VCO2 intercept in control and COPD categorized by GOLD. A; the COPD stages 1-2 and COPD stages 3-4 had higher intercepts in comparison to control. VE/VCO2 intercept increased across the severity spectrum of COPD (p<0.001). B; the nadir was increased in COPD stages 1-2 and almost stable in COPD stages 3-4 in comparison to control. C; compared to control, the slope was increased in COPD stages 1-2 and decreased in COPD stages 3-4 (26.84±4.96). VE: minute ventilation; VCO2: carbon dioxide output.
Correlations between $\dot{V}E/\dot{V}CO_2$ intercept and peak $\dot{V}E/MVV$ and peak $\dot{V}O_2$/watt in the entire study group. (A) $\dot{V}E/\dot{V}CO_2$ intercept vs. peak $\dot{V}E/MVV$ ($r=0.489$, $p<0.001$); (B) $\dot{V}E/\dot{V}CO_2$ intercept vs. peak $\dot{V}O_2$/watt ($r=0.354$, $p<0.01$). MVV: maximal voluntary ventilation; $\dot{V}E$: minute ventilation; $\dot{V}CO_2$: carbon dioxide output.
Correlations between the VE/VCO2 intercept and LH and airflow limitation (A) VE/VCO2 intercept vs. FEV1 % predicted ($r=-0.606$, $p<0.001$); (B) VE/VCO2 intercept vs. IC/TLC (%) ($r=-0.574$, $p<0.01$); (C) VE/VCO2 intercept vs. RV/TLC (%) ($r=0.588$, $p<0.001$); (D) VE/VCO2 intercept vs. peak VT/TLC ($r=-0.585$, $p<0.001$). FEV1: forced expiratory volume in 1s; IC: inspiratory capacity; RV: residual volume; TLC: total lung capacity; VE: minute ventilation; VCO2: carbon dioxide output.